Sample Size Benefits of Replicate Design with ABE [Power / Sample Size]

posted by dshah  – India/United Kingdom, 2023-05-25 11:56 (308 d 16:05 ago) – Posting: # 23569
Views: 1,074

HI Sereng!


❝ (1) If you conduct a full replicate crossover design BE study (T x 2, R x 2, e.g., TRTR|RTRT) is there any sample size efficiency (fewer patients required) with ABE analysis or is it no different (in terms of sample size) than a non-replicate crossover design BE study (T x1, R x 1) with ABE analysis.


The number of observations will be same but the sample size will be half in fully replicate design compared to standard CO study.

❝ (2) For demonstrably HVD (WSV >30%), why do some product specific guidance for ANDA suggest (or allow) full replicate designs and others do not mention this approach?


For HVD, the fully replicate/partial replicate can be helpful for widening of 90% CI limit based on regulatory agency for particular PK parameters. Ethically, due to widening of 90% CI, the sample size will be less than if it has be to standard limit of 80-125%.

❝ (3) For demonstrably HVD (WSV >30%), why do some Clinical Divisions object to use of full replicate design studies in 505(b)(2) NDAs?

Not aware of any. Can you share the link?

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
76 visitors (0 registered, 76 guests [including 6 identified bots]).
Forum time: 03:01 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5